Patents by Inventor Ralph Rivero

Ralph Rivero has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzimidazole derivatives as PI3 kinase inhibitors
    Patent number: 10660898
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: May 26, 2020
    Assignee: GLAXOSMITHKLINE LLC
    Inventors: Rosanna Tedesco, Junya Qu, Robert Sanchez, Ralph A. Rivero
  • BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS
    Publication number: 20190255064
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 22, 2019
    Inventors: Rosanna TEDESCO, Junya QU, Robert SANCHEZ, Ralph A. RIVERO
  • Benzimidazole derivatives as PI3 kinase inhibitors
    Patent number: 10314845
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: June 11, 2019
    Assignee: GlaxoSmithKline LLC
    Inventors: Rosanna Tedesco, Junya Qu, Robert Sanchez, Ralph A. Rivero
  • Benzimidazole Derivatives as PI3 Kinase Inhibitors
    Publication number: 20180263994
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Application
    Filed: January 9, 2018
    Publication date: September 20, 2018
    Inventors: Rosanna TEDESCO, Junya QU, Robert SANCHEZ, Ralph A. RIVERO
  • Benzimidazole derivatives as PI3 kinase inhibitors
    Patent number: 9872860
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: January 23, 2018
    Assignee: GLAXOSMITHKLINE LLC
    Inventors: Junya Qu, Ralph A. Rivero, Robert Sanchez, Rosanna Tedesco
  • Benzimidazole Derivatives As PI3 Kinase Inhibitors
    Publication number: 20170112844
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Application
    Filed: September 3, 2015
    Publication date: April 27, 2017
    Inventors: Rosanna TEDESCO, Junya QU, Robert SANCHEZ, Ralph A. RIVERO
  • Benzimidazole derivatives as PI3 kinase inhibitors
    Patent number: 9156797
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: October 13, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: Junya Qu, Ralph A. Rivero, Robert Sanchez, Rosanna Tedesco
  • Benzimidazole Derivatives As PI3 Kinase Inhibitors
    Publication number: 20150246889
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Application
    Filed: May 15, 2015
    Publication date: September 3, 2015
    Inventors: Junya Qu, Ralph A. Rivero, Robert Sanchez, Rosanna Tedesco
  • Pyrazolopyrimidine derivatives as PI3 kinase inhibitors
    Patent number: 9096605
    Abstract: PI3K? selective compounds having the structure
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: August 4, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: Hong Lin, Juan Ignacio Luengo, Michael Lee Moore, Junya Qu, Ralph A. Rivero, Rosanna Tedesco, Hongyi Yu
  • Benzimidazole derivatives as PI3 kinase inhibitors
    Patent number: 9062003
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: June 23, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: Junya Qu, Ralph A. Rivero, Robert Sanchez, Rosanna Tedesco
  • Benzimidazole Derivatives As PI3 Kinase Inhibitors
    Publication number: 20140378456
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Application
    Filed: September 9, 2014
    Publication date: December 25, 2014
    Inventors: Junya Qu, Ralph A. Rivero, Robert Sanchez, Rosanna Tedesco
  • Imidazopyridine derivatives as PI3 kinase
    Patent number: 8906910
    Abstract: This invention relates to the use of imidizopyridine derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of imidizopyridines in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective imidizopyridine compounds for treating cancer.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: December 9, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Ralph A. Rivero, Rosanna Tedesco
  • Imidazopyridine Derivatives As PI3 Kinase
    Publication number: 20140323480
    Abstract: This invention relates to the use of imidizopyridine derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of imidizopyridines in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective imidizopyridine compounds for treating cancer.
    Type: Application
    Filed: October 16, 2012
    Publication date: October 30, 2014
    Inventors: Ralph A. Rivero, Rosanna Tedesco
  • Benzimidazole derivatives as PI3 kinase inhibitors
    Patent number: 8865912
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: October 21, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Junya Qu, Ralph A. Rivero, Robert Sanchez, Rosanna Tedesco
  • Benzimidazole boronic acid derivatives as PI3 kinase inhibitors
    Patent number: 8778937
    Abstract: This invention relates to the use of benzimidazole boronic acid derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazole boronic acids in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazole boronic acid compounds for treating cancer.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: July 15, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Ralph A. Rivero, Rosanna Tedesco, Juan Ignacio Luengo
  • Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors
    Publication number: 20140187545
    Abstract: PI3K? selective compounds having the structure
    Type: Application
    Filed: June 29, 2012
    Publication date: July 3, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Hong Lin, Juan Luengo, Michael Lee Moore, Junya Qu, Ralph A. Rivero, Rosanna Tedesco, Hongyi Yu
  • Benzimidazole Derivatives As PI3 Kinase Inhibitors
    Publication number: 20140142321
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Application
    Filed: January 27, 2014
    Publication date: May 22, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Junya Qu, Ralph A. Rivero, Robert Sanchez, Rosanna Tedesco
  • Benzimidazole derivatives as PI3 kinase inhibitors
    Patent number: 8674090
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: March 18, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Junya Qu, Ralph A. Rivero, Robert Sanchez, Rosanna Tedesco
  • Benzimidazole Derivatives As PI3 Kinase Inhibitors
    Publication number: 20140018534
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Application
    Filed: September 19, 2013
    Publication date: January 16, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Junya Qu, Ralph A. Rivero, Robert Sanchez, Rosanna Tedesco
  • Benzimidazole derivatives as PI3 kinase inhibitors
    Patent number: 8541411
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: September 24, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Junya Qu, Ralph A. Rivero, Robert Sanchez, Rosanna Tedesco